Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths

John J. Leddy, James Waxmonsky, Robert J. Salis, Rocco A. Paluch, Elizabeth M. Gnagy, Patrick Mahaney, Richard Erbe, William E. Pelham, Leonard H. Epstein

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: There are individual differences in the effects of methylphenidate (MPH), a dopamine (DA) transport inhibitor, on appetite in children with attention-deficit/hyperactivity disorder (ADHD). One potential moderating factor is variation in brain DA activity, which is influenced by dopamine-related genes: the DA transporter (DAT) (SLC6A3), the DA D2 receptor (DRD2), and the DA D4 receptor (DRD4) genes. The purpose of this study was to explore the relationship between dopamine-related gene polymorphisms and food consumption in ADHD children receiving varying doses of MPH. Methods: In a randomized, within-subject, double-blind design, 58 ADHD children (ages 6-12 years) received placebo, 0.15, 0.3, or 0.6mg/kg of MPH three times daily over 9 weeks. Observations of percent lunch consumed as a function of dopamine-related genotypes and MPH dose were analyzed using mixed effects regression models. Results: A significant dose-response reduction in eating was observed across all genotypes (p<0.001). There was an interaction of DAT SLC6A3 and DRD2 genotypes and dose, because 9/9 DAT children showed a stronger effect of dose when compared with the 9/10 and 10/10 children (p<0.001) and DRD2 A2/A2 children showed a stronger effect of dose when compared with A1/A1 and A1/A2 children combined (p=0.007). There was no significant interaction of dose by DRD4 genotype. Conclusions: Lunch consumption decreased as a function of MPH dose. DA-related genotypes associated with greater brain DA signaling moderated the influence of drug on consumption. These results provide information relevant to predicting which children are likely to experience the greatest appetite suppression when taking MPH.

Original languageEnglish (US)
Pages (from-to)127-136
Number of pages10
JournalJournal of Child and Adolescent Psychopharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Dopamine
Eating
Genotype
varespladib methyl
Lunch
Appetite
Dopamine D4 Receptors
Genes
Dopamine Plasma Membrane Transport Proteins
Dopamine D2 Receptors
Brain
Individuality
Placebos
Food

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Leddy, John J. ; Waxmonsky, James ; Salis, Robert J. ; Paluch, Rocco A. ; Gnagy, Elizabeth M. ; Mahaney, Patrick ; Erbe, Richard ; Pelham, William E. ; Epstein, Leonard H. / Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. In: Journal of Child and Adolescent Psychopharmacology. 2009 ; Vol. 19, No. 2. pp. 127-136.
@article{4564f019d6a445e2944240ffdeed3011,
title = "Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths",
abstract = "Objective: There are individual differences in the effects of methylphenidate (MPH), a dopamine (DA) transport inhibitor, on appetite in children with attention-deficit/hyperactivity disorder (ADHD). One potential moderating factor is variation in brain DA activity, which is influenced by dopamine-related genes: the DA transporter (DAT) (SLC6A3), the DA D2 receptor (DRD2), and the DA D4 receptor (DRD4) genes. The purpose of this study was to explore the relationship between dopamine-related gene polymorphisms and food consumption in ADHD children receiving varying doses of MPH. Methods: In a randomized, within-subject, double-blind design, 58 ADHD children (ages 6-12 years) received placebo, 0.15, 0.3, or 0.6mg/kg of MPH three times daily over 9 weeks. Observations of percent lunch consumed as a function of dopamine-related genotypes and MPH dose were analyzed using mixed effects regression models. Results: A significant dose-response reduction in eating was observed across all genotypes (p<0.001). There was an interaction of DAT SLC6A3 and DRD2 genotypes and dose, because 9/9 DAT children showed a stronger effect of dose when compared with the 9/10 and 10/10 children (p<0.001) and DRD2 A2/A2 children showed a stronger effect of dose when compared with A1/A1 and A1/A2 children combined (p=0.007). There was no significant interaction of dose by DRD4 genotype. Conclusions: Lunch consumption decreased as a function of MPH dose. DA-related genotypes associated with greater brain DA signaling moderated the influence of drug on consumption. These results provide information relevant to predicting which children are likely to experience the greatest appetite suppression when taking MPH.",
author = "Leddy, {John J.} and James Waxmonsky and Salis, {Robert J.} and Paluch, {Rocco A.} and Gnagy, {Elizabeth M.} and Patrick Mahaney and Richard Erbe and Pelham, {William E.} and Epstein, {Leonard H.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1089/cap.2008.046",
language = "English (US)",
volume = "19",
pages = "127--136",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. / Leddy, John J.; Waxmonsky, James; Salis, Robert J.; Paluch, Rocco A.; Gnagy, Elizabeth M.; Mahaney, Patrick; Erbe, Richard; Pelham, William E.; Epstein, Leonard H.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 19, No. 2, 01.04.2009, p. 127-136.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths

AU - Leddy, John J.

AU - Waxmonsky, James

AU - Salis, Robert J.

AU - Paluch, Rocco A.

AU - Gnagy, Elizabeth M.

AU - Mahaney, Patrick

AU - Erbe, Richard

AU - Pelham, William E.

AU - Epstein, Leonard H.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Objective: There are individual differences in the effects of methylphenidate (MPH), a dopamine (DA) transport inhibitor, on appetite in children with attention-deficit/hyperactivity disorder (ADHD). One potential moderating factor is variation in brain DA activity, which is influenced by dopamine-related genes: the DA transporter (DAT) (SLC6A3), the DA D2 receptor (DRD2), and the DA D4 receptor (DRD4) genes. The purpose of this study was to explore the relationship between dopamine-related gene polymorphisms and food consumption in ADHD children receiving varying doses of MPH. Methods: In a randomized, within-subject, double-blind design, 58 ADHD children (ages 6-12 years) received placebo, 0.15, 0.3, or 0.6mg/kg of MPH three times daily over 9 weeks. Observations of percent lunch consumed as a function of dopamine-related genotypes and MPH dose were analyzed using mixed effects regression models. Results: A significant dose-response reduction in eating was observed across all genotypes (p<0.001). There was an interaction of DAT SLC6A3 and DRD2 genotypes and dose, because 9/9 DAT children showed a stronger effect of dose when compared with the 9/10 and 10/10 children (p<0.001) and DRD2 A2/A2 children showed a stronger effect of dose when compared with A1/A1 and A1/A2 children combined (p=0.007). There was no significant interaction of dose by DRD4 genotype. Conclusions: Lunch consumption decreased as a function of MPH dose. DA-related genotypes associated with greater brain DA signaling moderated the influence of drug on consumption. These results provide information relevant to predicting which children are likely to experience the greatest appetite suppression when taking MPH.

AB - Objective: There are individual differences in the effects of methylphenidate (MPH), a dopamine (DA) transport inhibitor, on appetite in children with attention-deficit/hyperactivity disorder (ADHD). One potential moderating factor is variation in brain DA activity, which is influenced by dopamine-related genes: the DA transporter (DAT) (SLC6A3), the DA D2 receptor (DRD2), and the DA D4 receptor (DRD4) genes. The purpose of this study was to explore the relationship between dopamine-related gene polymorphisms and food consumption in ADHD children receiving varying doses of MPH. Methods: In a randomized, within-subject, double-blind design, 58 ADHD children (ages 6-12 years) received placebo, 0.15, 0.3, or 0.6mg/kg of MPH three times daily over 9 weeks. Observations of percent lunch consumed as a function of dopamine-related genotypes and MPH dose were analyzed using mixed effects regression models. Results: A significant dose-response reduction in eating was observed across all genotypes (p<0.001). There was an interaction of DAT SLC6A3 and DRD2 genotypes and dose, because 9/9 DAT children showed a stronger effect of dose when compared with the 9/10 and 10/10 children (p<0.001) and DRD2 A2/A2 children showed a stronger effect of dose when compared with A1/A1 and A1/A2 children combined (p=0.007). There was no significant interaction of dose by DRD4 genotype. Conclusions: Lunch consumption decreased as a function of MPH dose. DA-related genotypes associated with greater brain DA signaling moderated the influence of drug on consumption. These results provide information relevant to predicting which children are likely to experience the greatest appetite suppression when taking MPH.

UR - http://www.scopus.com/inward/record.url?scp=65249135898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249135898&partnerID=8YFLogxK

U2 - 10.1089/cap.2008.046

DO - 10.1089/cap.2008.046

M3 - Article

VL - 19

SP - 127

EP - 136

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -